MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
"Triple Helix" Innovation Model
4. Triple Helix _ Capture Strategies
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Research Triangle, North Carolina
Humacyte, Inc. (NASDAQ:HUMA)*
Organization & Developments: Humacyte
Parents
Humacyte, Inc. (NASDAQ:HUMA)*
Children
*Company Uses a Human Cell-based Technique to Develop Synthetic Blood Vessels that Can Be Transplanted in Patients with Diseases,
*Primarily focused on developing products for vascular disease and for therapeutic filling and soft tissue repair.
*Tissue-engineered vascular grafts (TEVGs)
*Uses its innovative and proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues.
2010: Maker Of Artificial Blood Vessels, Raises $12M
2017: Humacyte Receives Award from the Medical Technology Enterprise Consortium (MTEC)
2020: Humacyte’s Bioengineered Blood Vessel Implanted by Clinicians at Walter Reed to Restore Blood Circulation to Retired Military Veteran’s Leg - MTEC
2022: Humacyte (HUMA) Investor Presentation - Slideshow
2022: Humacyte: Intriguing Potential_seekingalpha.com
2023: Humacyte Gets A Lifeline_ seekingalpha.com
2023: Humacyte: Upcoming BLA, Pivotal Data, Decent Cash, Excellent Opportunity_ seekingalpha.com
2023: MTEC-Impact-Story-Humacyte-FINAL
2024: FDA Approves Humacyte's Groundbreaking Bioengineered Blood Vessel Treatment SYMVESS in Historic First
2024: Humacyte: FDA Waiting Game Bleeding Company Dry
2024: Humacyte: Navigating The FDA Uncertainty And ATEV's Potential
2024: Humacyte: Surprise PDUFA Delay, Low Cash, Excellent Product
2024: Humacyte's SWOT analysis: HAV tech drives growth amid safety concerns Investing.com
2024: Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)
2024: Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)
2024: Humacyte’s ATEV granted US FDA Regenerative Medicine Advanced Therapy designation for advanced PAD
2024: Revisiting Humacyte
2024: US FDA extends review of Humacyte's blood vessel implant
2025: Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey
2025: Humacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A Beginning
2025: Humacyte: Revenue Ramp From Symvess Incoming
2025: Humacyte: Upside Potential, But I Will Wait For Revenue Trends
2026: Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist
Jumps
*Key People: Humacyte
Finance & Acquisitions: Humacyte